Acute myeloid leukemia (AML) is commonly diagnosed in the elderly. Treatment of AML frequently requires hematopoietic stem cell transplantation (HSCT), which is associated with significant treatment related toxicity and is considered to be too intense for older patients. However, with the development of reduced intensity conditioning, patients of increasing age are now considered for HSCT. We present a case of relapsed. AML in a 76-year-old woman who was successfully treated with allogeneic stem cell transplantation. She endured the process without significant complications and achieved a durable treatment response, demonstrating the feasibility of allogeneic HSCT in patients with very advanced age. We will also share current utility of Taiwan stem cell bank in the same presentation

Pei-Ying Hsieh completed her MD at the age of 25 years from Chinese Medical University, Taiwan. She completed training of hematology and oncology in Taiwan University Hospital in 2002-2008. She has served in Far Eastern Memorial Hospital, Taiwan since 2008. She is frequently invited as a reviewer of Journal of Cancer Research and Practice